Peptide Science Australian Capital Territory

Peptide Science Australian Capital Territory: A Hub of Innovation and Research

The Australian Capital Territory (ACT), anchored by the nation’s capital Canberra, has emerged as a significant centre for peptide science in Australia. While smaller than the biomedical hubs of Melbourne and Sydney, the ACT boasts a concentration of world-class research institutions, regulatory bodies, and manufacturing capabilities that position it as a key player in the peptide and protein science landscape. This article explores the research Peptide Science Australian Capital Territory institutions, regulatory framework, manufacturing capabilities, and clinical applications that define peptide science in the ACT.

The ARC Centre of Excellence for Innovations in Peptide and Protein Science

At the heart of Peptide Science Australian Capital Territory is the ARC Centre of Excellence for Innovations in Peptide and Protein Science (CIPPS) . Funded through the Australian Research Council’s Centres of Excellence scheme, CIPPS represents a $35 million investment over seven years from the Australian Government, with an additional $54 million in cash and in-kind contributions from national and international partners.

CIPPS operates with a clear and ambitious vision: to discover new peptides and proteins from Australia’s diverse flora and fauna, decode their biological functions, and develop new peptides and proteins to address challenges in health, agriculture and industry. The Centre has assembled leading researchers from diverse disciplines to create a sustainable national research centre that will drive new Australian industries and train the next generation of researchers.

The Centre’s research is organised around three flagship programs. Flagship 1 focuses on unlocking the peptide universe of unique Australian animals and plants, identifying those that may be repurposed for human benefit. Flagship 2 involves programming peptides for bioavailability and localisation, developing enabling technologies of labels and probes to study cell membrane interactions. Flagship 3 creates biosynthetic technologies for peptide and protein engineering to translate them into products for a range of industries. Collectively, these flagships address the grand challenge of making peptides orally bioavailable and delivering them to targeted locations, including intracellular targets.

CIPPS has forged partnerships with industry leaders spanning Big Pharma (AstraZeneca, Novo Nordisk), Ag Biotech (Innovate Ag), instrumentation (AB Sciex and Vapourtec), manufacturing (Almac, CSIRO), food science (CSIRO) and education (Questacon). This investment is expected to position Australia as an international hub for peptide and protein science.

The Australian National University: A Research Powerhouse

The Australian National University (ANU) in Canberra serves as the primary academic institution driving peptide research in Peptide Science Australian Capital Territory. The Research School of Chemistry at ANU hosts numerous research groups dedicated to Peptide Science Australian Capital Territory.

The Nitsche Lab at ANU is a dynamic, interdisciplinary research group that overcomes traditional boundaries between organic, inorganic and biological chemistry to develop next-generation peptide and protein drug candidates. Associate Professor Christoph Nitsche, an ARC Future Fellow, focuses on the biocompatible modification of peptides and proteins to advance drug discovery for infectious diseases and the development of theranostic agents. His work has led to the first peptide-based protease inhibitors that significantly inhibit dengue virus replication in cell culture.

The Malins Group at ANU is interested in several anti-cancer, antimalarial, and antibiotic peptides, working on the synthesis of peptide natural products as next-generation drug leads. Dr Lara Malins, who was awarded the ACT Young Tall Poppy Award for her research unlocking peptides and proteins for their therapeutic potential, leads this effort.

Dr Pritha Ghosh, a Postdoctoral Research Fellow at the Research School of Chemistry, focuses on the design and chemical synthesis of new classes of constrained peptides and proteins targeting infectious diseases. Hayden Bell, a PhD student at ANU, is developing new techniques for the cyclisation of peptides, including the exploration and use of supramolecular chemistry in peptide synthesis.

A significant research project at ANU, “Peptide Therapeutics: Next-Generation Antibiotics, Antimalarials and Anticancer Agents,” aims to unlock the chemical tools needed to produce and optimise bioactive peptides as next-generation drug leads. This project, funded with $4,821,004 from the Commonwealth Australian Renewable Energy Agency, runs from 2025 to 2030. Another fellowship program focuses on “Backbone Editing Strategies: Underutilised Tools for Peptide Drug Discovery,” developing synthetic chemistry tools to optimise the drug-like properties of peptides.

Regulatory Framework: The ACT’s Distinctive Legal Position

The regulatory environment for peptides in the ACT is notably stringent. Peptides listed in Schedule 4 of the Poisons Standard are considered “prescription-only medicines” or “declared substances” under the Medicines, Poisons and Therapeutic Goods Act 2008 (ACT) .

Possession of peptides without a valid prescription in the ACT carries severe penalties. Under section 36 of the Act, the maximum penalty is a $66,000 fine and/or two years imprisonment. Supplying peptides without authorisation is also an offence under section 26 of the Act. This places the ACT among the jurisdictions with the strictest penalties for peptide-related offences in Australia, with fines significantly higher than those in New South Wales ($2,200), Victoria ($1,975.90), and Queensland ($32,260).

Dr Chloe Larcombe, an Evaluator at the Therapeutic Goods Administration (TGA) in Canberra, exemplifies the intersection of regulatory oversight and peptide science in the ACT. Her research focuses on developing new synthetic methods for the late-stage modification of peptides, particularly solid-phase peptide synthesis linkers for C-terminal peptide modification.

Interest in peptide therapies has grown across Canberra and the ACT, with individuals seeking information on accessingPeptide Science Australian Capital Territory regulated healthcare system. Telehealth services facilitate consultations with AHPRA-registered practitioners who assess whether peptide therapy may be appropriate, with medications dispensed through Australian compounding pharmacies and delivered via temperature-controlled courier.

CSIRO and Industry Collaboration

The Commonwealth Scientific and Industrial Research Organisation (CSIRO) , Australia’s national science agency, maintains a significant presence in peptide science through its Canberra-based operations.

Dr Paul Savage, Research Director of the Biomedical Manufacturing Platform at CSIRO, applies cutting-edge proteomics methodologies to characterise the structure, function, post-translational modifications and molecular interactions of therapeutic peptides, proteins and protein complexes. His work focuses on the development of novel engineered therapeutic proteins, especially antibodies, for the treatment of various diseases, and the application of novel conjugation/ligation technologies for the synthesis of bespoke “designer” proteins with novel functional activities.

Dr Amanda Dawson, a CERC Fellow at CSIRO, researches the interactions between proteins, peptides and microplastics during human digestion, specifically investigating protein or peptide binding, diversity, permanence and how protein-microplastic complexes interact with living systems.

Dr Andrew Kotze at CSIRO Agriculture and Food focuses on the control of insect and helminth parasites of livestock and humans, aiming to discover new anthelmintic and insecticidal agents.

Professor Michelle Colgrave, Professor of Food and Agricultural Proteomics at CSIRO, uses proteomics—the study of proteins using mass spectrometry—to identify, characterise and quantify key proteins and peptides that benefit Australia’s food and agriculture industries and improve human health.

Peptide Manufacturing in the ACT

While the ACT is not home to large-scale peptide manufacturing facilities, Auspep represents a notable exception. Auspep is the only GMP-accredited manufacturer of peptides in Australia, specialising in the development and production of synthetic peptides as active pharmaceutical ingredients (APIs).

With over 20 years of experience, Auspep supplies peptides and related products to researchers around the world. The company has the capability to manufacture peptides from clinical scale (milligrams) to commercial scale (kilograms) using solid phase peptide synthesis, with GMP facilities containing multiple rooms for batch-specific tasks. Auspep’s vision is to be a global manufacturer of high-quality custom synthetic peptides, serving as tools for research, clinical trials and drug development.

Notably, Auspep operates under strict regulations as a registered manufacturer of APIs and is unable to sell products to anyone but bona fide research or registered drug manufacturing bodies.

FytoBio, a Canberra-based company, is creating scalable technology to supply food-grade recombinant proteins for cultivated meat, seafood, leather and cosmetics.

Clinical Research and Therapeutic Applications

Peptide Science in the Australian Capital Territory is actively engaged in peptide-related clinical research. A project conducted in collaboration with the Canberra Hospital aims to assess the antimicrobial efficacy of engineered antimicrobial peptides against a library of clinical isolates, including antimicrobial-resistant strains. This project examines the antimicrobial effect of 10 engineered peptides against 10 species of clinically important bacteria obtained from the Canberra Hospital.

Peptide therapeutics are increasingly being explored for conditions including obesity, diabetes, and chronic kidney disease. A Phase 3 randomised trial is evaluating KAI-9531, a peptide therapeutic, administered once weekly compared with semaglutide and placebo in participants living with obesity. Another trial is investigating glucagon-like peptide-1 (GLP-1) domain therapies, with semaglutide being added to test combination treatments for chronic kidney disease.

The Canberra Protein Group (CPG), a Special Interest Group of the Australian Society for Biochemistry and Molecular Biology, brings together protein scientists across the ACT and surrounding region. In collaboration with CIPPS, the group hosts workshops introducing new approaches in peptide and protein science.

Future Directions and Outlook

The future of Peptide Science Australian Capital Territory appears promising. A project titled “Greening the production of peptides and proteins” aims to develop a green and sustainable synthetic platform for the production of peptide and protein molecules, benefiting Australia’s growing biotechnology and pharmaceutical manufacturing sectors.

The establishment of a new ARC Centre of Excellence for Advanced Peptide and Protein Engineering (CAPE) will further strengthen Australia’s position in the field. CAPE aims to transform the engineering and translation of peptides and proteins for human and planetary benefit, uncovering unique molecules from Australia’s flora and fauna using advanced computational methods and designing “new-to-nature” structures.

The Australian Peptide Conference, scheduled for October 2025, will bring together researchers from across the country. With CIPPS, ANU, CSIRO, and the TGA all based in Canberra, the ACT is uniquely positioned as a centre where peptide research, regulation, and policy intersect.

Conclusion

The Peptide Science in the Australian Capital Territory, despite its small geographical size, punches well above its weight in peptide science. Through the ARC Centre of Excellence for Innovations in Peptide and Protein Science, the research excellence of the Australian National University, the applied science of CSIRO, the regulatory oversight of the TGA, and the specialised manufacturing of Auspep, the ACT has established itself as a critical node in Australia’s peptide science ecosystem. The stringent regulatory framework ensures that peptide therapeutics are accessed only through legitimate medical pathways, while ongoing research continues to unlock the therapeutic potential of these remarkable molecules for the benefit of human health, agriculture, and industry.